iCAD Inc.

iCAD Inc. is a medical-device company headquartered in Nashua, New Hampshire, whose technologies are intended to support cancer detection and treatment. Its principal areas have included computer-aided detection and analysis for breast, prostate, and colorectal cancers, together with hardware and software used in radiation therapy. The company’s products are designed to assist clinicians rather than replace physician judgment, with applications spanning medical imaging, oncology workflows, and localized cancer treatment. The business began in 1984 under the name Howtek, Inc. Howtek initially developed, manufactured, and marketed digitizing systems and scanners that converted printed, photographic, and other physical images into digital files. These systems served graphic-arts, photo-finishing, and medical customers. Between 1984 and 2000, the company worked on improving digital-image quality while reducing the cost and complexity of digitization equipment. In 2001, anticipating weaker long-term prospects in graphic arts and photo finishing, Howtek shifted its strategic focus to medical imaging. It acquired Intelligent Systems Software, Inc. (ISSI), whose technology included a U.S. Food and Drug Administration-cleared computer-aided detection system for breast cancer. It later acquired Qualia Computing, Inc. and its subsidiary CADx Systems, Inc. These transactions consolidated significant breast-imaging computer-aided-detection capabilities and formed the foundation for the iCAD medical-imaging business. The company broadened its oncology activities in December 2010 by acquiring Xoft, Inc. and the Axxent Electronic Brachytherapy System. Xoft’s technology delivered electronic brachytherapy directly to a treatment site, with the objective of limiting radiation exposure to surrounding tissue and shortening treatment courses in appropriate clinical settings. The system had U.S. clearance for certain breast, endometrial, and skin-cancer applications, as well as other uses where radiation therapy was indicated. This acquisition gave iCAD a second major business line alongside image-analysis software: localized radiation treatment. The Xoft business later became associated with a significant product-safety controversy involving the Axxent FlexiShield Mini accessory. Reports described tungsten particles remaining in the breast tissue and chest muscles of some patients in study settings. iCAD and the FDA recalled the accessory and investigated the matter. Product-liability litigation followed, and the issue generated legal expenses and investor concern. The supplied historical material does not establish the final legal outcome or the full long-term commercial impact. iCAD also pursued reimbursement and distribution strategies to expand adoption. In 2012, reimbursement for the Xoft Axxent Electronic Brachytherapy System was reported to have increased substantially under U.S. Medicare policy. The change attracted investor attention and was followed by a sharp movement in the company’s stock, although the supplied material does not provide a verified closing share price or a complete market-performance history. The company also sought distribution through large original-equipment-manufacturer partners, including General Electric, and applied its algorithms to digital mammography and CT colonography. In 2020, iCAD reported continued investment in targeted growth initiatives, including work related to brain cancer. For the first quarter of that year, the company reported revenue of $6.6 million, a GAAP net loss of $11.8 million, a non-GAAP adjusted net loss of $3.9 million, and cash and cash equivalents of $14.3 million. It completed a registered direct offering in April 2020 for approximately $12.5 million in gross proceeds. These figures are historical and should not be treated as current financial information. On July 17, 2025, it was announced that iCAD had been acquired by DeepHealth, a wholly owned subsidiary of RadNet, Inc. The supplied sources do not specify whether the iCAD brand remains commercially active as an independent operating brand, has been fully integrated, or continues under another corporate structure. Its historical identity is therefore best understood as a specialized oncology-technology brand spanning computer-aided detection, medical imaging, and electronic brachytherapy.

iCAD traces its origins to Howtek, Inc., founded in 1984 as a developer of digitizing systems and scanners. Howtek’s equipment converted hard-copy images into digital data for graphic arts, photo finishing, and medical uses. During the period from 1984 through 2000, the company concentrated on improving image quality and making digitization systems less expensive and easier to use. In 2001, Howtek decided to leave its traditional graphic-arts and photo-finishing emphasis and concentrate on medical imaging. The decision reflected management’s expectation that those earlier markets would decline. The company acquired Intelligent Systems Software, Inc., whose portfolio included a breast-cancer computer-aided-detection system cleared by the FDA. It subsequently acquired Qualia Computing, Inc. and its subsidiary CADx Systems, Inc. The transactions combined important capabilities in breast-cancer image analysis and helped establish the company as a dedicated medical-imaging technology provider. The iCAD business focused on software and algorithms intended to help radiologists and other healthcare professionals identify suspicious findings. Its areas of interest expanded beyond breast imaging to include prostate and colorectal cancer applications. The company also worked on digital mammography and CT colonography analysis and sought distribution through large OEM partners, including General Electric. In December 2010, iCAD acquired Xoft, Inc., adding the Axxent Electronic Brachytherapy System to its portfolio. Unlike the company’s image-analysis products, the Xoft platform was a treatment technology. It delivered electronic brachytherapy at or near a cancer site and was promoted as a way to provide targeted radiation while reducing exposure to nearby healthy tissue. The system had U.S. clearance for certain early-stage breast, endometrial, and skin-cancer applications and potentially other radiation-treatment indications. The Xoft acquisition was followed by a product-safety problem involving the Axxent FlexiShield Mini. Reports in 2011 said that some patients had tungsten particles in breast tissue and chest muscles after treatment in study settings. Twenty-seven reported cases were associated with Hoag Memorial Hospital Presbyterian in California, while two additional patients were described in connection with a study at Karmanos-Crittenton Cancer Center in Michigan. The accessory was recalled by iCAD and the FDA, and the consequences were investigated. Beginning in February 2011, product-liability suits were filed in Orange County Superior Court. A company regulatory filing later described multiple Jane Doe complainants and related spouses. The supplied sources do not provide a definitive final resolution. The issue also affected investor perceptions. Commentary in 2011 identified potential liability from the recall as a risk even while noting the company’s revenue growth. iCAD reported legal and lawsuit-related expenses of $1.5 million during the first nine months of 2011 in the material supplied. Later investment commentary characterized the remaining legal exposure as a limited concern, but that assessment was an analyst opinion rather than a final legal finding. In November 2012, iCAD reported a major increase in the U.S. reimbursement rate for the Xoft Axxent Electronic Brachytherapy System. The reimbursement development generated a rise in trading volume and substantial investor interest. The company continued to frame targeted radiation therapy as a growth opportunity as healthcare providers considered shorter and more localized treatment approaches for selected cancers. For the first quarter of 2020, iCAD reported $6.6 million in revenue, a GAAP net loss of $11.8 million, and a non-GAAP adjusted net loss of $3.9 million. It reported $14.3 million in cash and cash equivalents and completed a registered direct offering in April 2020 for approximately $12.5 million in gross proceeds. The company said it intended to keep investing in targeted growth initiatives, including brain-cancer applications. On July 17, 2025, DeepHealth, a wholly owned subsidiary of RadNet, announced the acquisition of iCAD. The available reference material does not describe the transaction’s financial terms, the continuing legal identity of iCAD, or whether all products and employees remained under the iCAD name. Accordingly, the company’s current independent operating status requires verification.

• 2025

  Acquisition by DeepHealth announced

  [1]iCAD Inc.en.wikipedia.org

  DeepHealth, a RadNet subsidiary, announced that it had acquired iCAD.

• 2020

  Capital raise and continued oncology investment

  [1]iCAD Inc.en.wikipedia.org

  The company reported first-quarter financial results, completed a registered direct offering, and stated that it would continue investing in targeted growth areas including brain cancer.

• 2012

  Higher reimbursement reported for Xoft

  [1]iCAD Inc.en.wikipedia.org

  iCAD reported a substantial increase in U.S. Medicare reimbursement for the Xoft Axxent Electronic Brachytherapy System.

• 2011

  FlexiShield Mini recall and litigation

  [1]iCAD Inc.en.wikipedia.org

  The Axxent FlexiShield Mini was recalled after reports of tungsten particles in the tissue of some patients, followed by product-liability lawsuits.

• 2010

  Xoft acquired

  [1]iCAD Inc.en.wikipedia.org

  iCAD acquired Xoft, Inc. and added the Axxent Electronic Brachytherapy System to its oncology portfolio.

• 2001

  Strategic shift to medical imaging

  [1]iCAD Inc.en.wikipedia.org

  Howtek moved away from graphic-arts and photo-finishing markets and focused on medical imaging, beginning with the acquisition of Intelligent Systems Software, Inc.

• 2001

  Qualia Computing and CADx Systems acquired

  [1]iCAD Inc.en.wikipedia.org

  The company acquired Qualia Computing, Inc. and its CADx Systems subsidiary, adding further breast-cancer computer-aided-detection capabilities.

• 1984

  Howtek founded

  [1]iCAD Inc.en.wikipedia.org

  The company was established as Howtek, Inc. to develop and market digitizing systems and scanners.

A specialist oncology-technology company positioned around earlier cancer detection, radiology workflow support, and more localized radiation treatment. Its historical differentiation came from combining image-analysis software with electronic brachytherapy equipment and from pursuing clinical distribution and reimbursement partnerships.

• Medical-imaging software

  Breast cancer computer-aided detection

  iCAD’s historical breast-imaging technologies analyzed mammographic and related medical images to identify suspicious patterns that might warrant closer review. These tools were intended to support radiologists by highlighting findings and improving workflow, not to make autonomous diagnoses. The business grew from technologies obtained through acquisitions of Intelligent Systems Software, Qualia Computing, and CADx Systems.

• Computer-aided detection

  Prostate and colorectal cancer analysis solutions

  The company applied image-analysis algorithms to additional oncology areas, including prostate and colorectal cancer. Its colorectal work included CT colonography analysis, while its wider product strategy sought to use computer-aided detection to help clinicians identify potentially malignant findings earlier in the diagnostic process.

• Radiation-therapy equipment

  Axxent Electronic Brachytherapy System

  Acquired through Xoft, the Axxent system delivered electronic brachytherapy at a cancer site or treatment location. It was intended to provide targeted radiation with limited exposure to surrounding healthy tissue and had U.S. clearance for selected breast, endometrial, and skin-cancer applications, among other possible uses.

• Radiation-therapy accessory

  Axxent FlexiShield Mini

  The FlexiShield Mini was an accessory used with the Axxent electronic brachytherapy platform. It became the subject of a 2011 recall after reports that tungsten particles had been left in the tissue of some patients treated in study settings. Its later commercial status is not established by the supplied sources.

• 2011

  Tungsten-particle contamination associated with FlexiShield Mini

  Reports stated that some patients treated with the Axxent FlexiShield Mini had hundreds of tiny tungsten particles in breast tissue and chest muscles. iCAD and the FDA recalled the accessory and investigated the matter. Product-liability litigation was filed in California, but the supplied sources do not establish the final outcome.

  Source

Read more

• 2025

  Acquisition by DeepHealthM&A

  Background

  iCAD had developed a portfolio spanning cancer detection, medical imaging, and radiation therapy.

  Action taken

  DeepHealth, a wholly owned subsidiary of RadNet, announced the acquisition of iCAD.

  Aftermath

  The available material does not specify the transaction terms, integration plan, or whether iCAD continues as an independent brand.

  Source

• 2012

  Pursuit of improved reimbursement for XoftOther

  Background

  Adoption of specialized radiation therapy depended partly on reimbursement levels from U.S. healthcare payers.

  Action taken

  The company announced that reimbursement for the Xoft Axxent Electronic Brachytherapy System had more than doubled under U.S. Medicare policy.

  Aftermath

  The announcement increased investor attention and trading activity, although the supplied sources do not provide a complete verified stock-price history.

  Source

• 2011

  Recall of FlexiShield MiniOther

  Background

  Reports indicated that tungsten particles could remain in the tissue of patients treated with the accessory in certain study settings.

  Action taken

  iCAD and the FDA executed a recall and investigated the product-safety issue.

  Aftermath

  Multiple product-liability suits were filed, and legal expenses became a reported business risk. The final resolution is not provided in the supplied material.

  Lawsuit and other legal expenses. $1.5 million (First nine months of 2011)

  Source

• 2010

  Acquisition of XoftM&A

  Background

  iCAD sought to expand beyond diagnostic image analysis into cancer treatment and radiation oncology.

  Action taken

  The company acquired Xoft, Inc. and its Axxent Electronic Brachytherapy System.

  Aftermath

  The transaction expanded iCAD’s oncology portfolio but was followed by a recall and litigation involving the FlexiShield Mini accessory.

  Source

• 2001

  Abandonment of primary graphic-arts focusStrategy

  Background

  Howtek anticipated deterioration in the graphic-arts and photo-finishing markets that had supported its original scanner business.

  Action taken

  The company redirected its main business toward medical imaging and acquired companies with breast-cancer computer-aided-detection technology.

  Aftermath

  The shift created the foundation for the later iCAD oncology-imaging brand.

  Source

1. 1iCAD Inc.en.wikipedia.org